Browse by author
Lookup NU author(s): Dr Andrew Harbottle
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Mitochondria and their associated genome are emerging as sophisticated indicators of prostate cancer (PCa) biology. Alterations in the mitochondrial genome (mtgenome) have been implicated in cell proliferation, metastatic behavior, androgen independence, as a signal for apoptosis, and as a predictor of biochemical recurrence. Somatic mutation patterns in complete mtgenomes are associated with prostate specific antigen levels (PSA) in PCa patients and a large-scale mtgenome deletion (3.4kb) is consistent with a prostate "cancerization" field effect. This review will focus on the biological characteristics of mitochondria and their direct clinical application to PCa. Mitochondrial science is currently influencing clinical PCa diagnostics and the rapid progress in this area indicates future, break-through contributions in the general field of oncology.
Author(s): Parr R, Mills J, Harbottle A, Creed J, Crewdson G, Reguly B, Guimont F
Publication type: Article
Publication status: Published
Journal: Discovery Medicine
Print publication date: 25/04/2013
ISSN (print): 1539-6509
ISSN (electronic): 1944-7930
Publisher: Discovery Medicine